Multiple sclerosis (MS) is the most common chronic inflammatory disease of the CNS in the Western world, and it affects up to 2.5 million people worldwide. This disease is the leading cause of ...

Shortly after intracerebral hemorrhage (ICH), significant inflammatory reactions promote formation and progression of perihematomal edema (PHE), with secondary brain injury. The hypothesis tested by ...

New data suggest halving the FDA-approved 0.5-mg dose of fingolimod (Gilenya, Novartis) is not as effective as either the higher dose or glatiramer acetate in the treatment of relapsing-remitting ...

A recent study sought to compare several available oral immunotherapies for the treatment of relapsing-remitting multiple sclerosis (MS). A recent study sought to compare several available oral ...

Fingolimod therapy can cause persistent heart rate slowing in patients with preexisting parasympathetic predominance due to autonomic dysfunction. A study of 34 RRMS patients found prolonged ...

Learn everything you need to know about Fingolimod-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 months with magnetic resonance imaging (MRI) ...

Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis. July 2019: Fingolimod is contraindicated during pregnancy and in women of childbearing ...

Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.

Review the side-effects of Fingolimod as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of fingolimod, having considered evidence on the nature of highly active relapsing–remitting multiple ...